Skip to main content

Advertisement

SpringerLink
Log in

Glucocorticoid use in rheumatoid arthritis

  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

More than 50 years after their discovery, glucocorticoids continue to be a mainstay of treatment for many patients with rheumatoid arthritis (RA). Although the short- and moderate-term efficacy of glucocorticoids in RA is seldom debated, increasing evidence favors a disease-modifying role of glucocorticoids. Despite renewed enthusiasm based on this newer long-term data, glucocorticoid use is marred substantially by the potential for many serious adverse events. Glucocorticoid-induced osteoporosis is one of the most predictable and serious complications for many chronic and some acute users. The correct identification of patients at high risk for bone complications and the institution of appropriate preventive measures may partially attenuate this adverse outcome.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Walsh LJ, Wong CA, Pringle M, Tattersfield AE: Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study. BMJ 1996, 313:344–346.

    PubMed  CAS  Google Scholar 

  2. Saag KG, Koehnke R, Caldwell JR, et al.: Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med 1994, 96:115–123.

    Article  PubMed  CAS  Google Scholar 

  3. Weusten BLAM, Jacobs JWG, Bijlsma JWJ: Corticosteroid pulse therapy in active rheumatoid arthritis. Semin Arthritis Rheum 1993, 23:183–192.

    Article  PubMed  CAS  Google Scholar 

  4. Buttgereit F, Wheling M, Burmester GR: A new hypothesis of modular glucocorticoid actions—steroid treatment of rheumatic diseases revisited. Arthritis Rheum 1998, 41:761–767.

    Article  PubMed  CAS  Google Scholar 

  5. Boumpas DT, Chrousos GP, Wilder RL, et al.: Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. Ann Intern Med 1993, 119:1198–1208.

    PubMed  CAS  Google Scholar 

  6. Barnes PJ, Adcock I: Anti-inflammatory actions of steroids: molecular mechanisms. Trends Pharmacol Sci 1993, 14:436–441.

    Article  PubMed  CAS  Google Scholar 

  7. Eggert M, Schulz M, Neeck G: Molecular mechanisms of glucocorticoid action in rheumatic autoimmune diseases. J Steroid Biochem Mol Biol 2001, 77:185–191. Sophisticated and clear overview of the state-of-the-art on mechanisms.

    Article  PubMed  CAS  Google Scholar 

  8. Derijk RH, Schaaf MJM, Turner G, et al.: A human glucocorticoid receptor gene variant that increases the stability of glucocorticoid receptor β-isoform mRNA is associated with rheumatoid arthritis. J Rheumatol 2001, 28:2383–2388.

    PubMed  CAS  Google Scholar 

  9. Kern JA, Laumb RT, Reed JC, et al.: Dexamethasone inhibition of interleukin-1beta production by human monocytes: posttranscriptional mechanisms. J Clin Invest 1988, 81:237–244.

    PubMed  CAS  Google Scholar 

  10. Cronstein BN, Kimmel SC, Levin RI, et al.: A mechanism for the anti-inflammatory effects of corticosteroids: the glucocorticoid receptor regulates leukocyte adhesion to endothelial cells and expression of endothelial-leukocyte adhesion molecule-1 and intercellular adhesion molecule 1. Proc Natl Acad Sci U S A 1992, 89:9991–9995.

    Article  PubMed  CAS  Google Scholar 

  11. Szczepanski A, Moatter T, Carley WW, Gerritsen ME: Induction of cyclooxygenase II in human synovial microvessel endothelial cells by interleukin-1: inhibition by glucocorticoids. Arthritis Rheum 1994, 37:495–503.

    Article  PubMed  CAS  Google Scholar 

  12. Van Gestel AM, Laan RFJM, Haagsma CJ, et al.: Low-dose oral steroids as bridge therapy in rheumatoid arthritis patients starting with parenteral gold: a randomized double-blind placebo-controlled trial. Br J Rheumatol 1995, 34:347–351.

    Article  PubMed  Google Scholar 

  13. Gotzsche PC, Johansen HK: Meta-analysis of short term low dose prednisolone versus placebo and non-steroidal antiinflammatory drugs in rheumatoid arthritis. BMJ 1998, 316:811–818.

    PubMed  CAS  Google Scholar 

  14. Saag KG, Criswell LA, Sems KM, et al.: Low-dose corticosteroids in rheumatoid arthritis: a meta-analysis of their moderate-term effectiveness. Arthritis Rheum 1996, 39:1818–1825.

    Article  PubMed  CAS  Google Scholar 

  15. Criswell LC, Saag KG, Sems KM, et al.: Rheumatoid Arthritis (RA): Moderate-term Low Dose Corticosteroids for Rheumatoid Arthritis (Cochrane Review). The Cochrane Library. Oxford: Update Software; 1999.

    Google Scholar 

  16. Kirwan JR, and the Arthritis and Rheumatism Council Low Dose Glucocorticoid Study Group: The effect of glucocorticoids on joint destruction in rheumatoid arthritis. N Engl J Med 1995, 333:142–146.

    Article  PubMed  CAS  Google Scholar 

  17. Boers M, Verhoven AC, Markusse HM, et al.: Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997, 350:309–318.

    Article  PubMed  CAS  Google Scholar 

  18. Hansen M, Podenphant J, Florescu A, et al.: A randomised trial of differentiated prednisolone treatment in active rheumatoid arthritis: clinical benefits and skeletal side effects. Ann Rheum Dis 1999, 58:713–718.

    PubMed  CAS  Google Scholar 

  19. van Everdingen AA, Jacobs JWG, van Reesema DR, Bijlsma JWJ:Low dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease modifying properties and side effects. A double-blind placebocontrolled clinical trial. Ann Intern Med 2002, 136:1–12. The first large-scale randomized controlled trial to demonstrate a disease-modifying effect of glucocorticoid monotherapy for the treatment of RA. Unlikely to be reproduced because of the available therapeutic options, which make this clever design outmoded.

    PubMed  Google Scholar 

  20. Rau R: Low dose steroid therapy in rheumatoid arthritis: a model for therapy of inflammatory diseases?—results of the LDPT study. Zeitschrift fur Rheumatologie 2001, 60:111–112. An important large study suggesting disease-modifying potential of glucocorticoids.

    Article  PubMed  CAS  Google Scholar 

  21. Kirwan JR: The relationship between synovitis and erosions in rheumatoid arthritis. Br J Rheum 1997, 36:225–228.

    Article  CAS  Google Scholar 

  22. Hickling P, Jacoby RK, Kirwan JR: Joint destruction after glucocorticoids are withdrawn in early rheumatoid arthritis. Br J Rheumatol 1998, 37:930–936.

    Article  PubMed  CAS  Google Scholar 

  23. Jacobs JWG, Greenen R, Evers AWM, et al.: Short term effects of corticosteroid pulse treatment on disease activity and the well being of patients with active rheumatoid arthritis. Ann Rheum Dis 2000, 60:61–64. A sequel, in some respects, to the Dutch COBRA study, further investigating the benefit of pulse therapy in RA.

    Article  Google Scholar 

  24. Lukert BP, Raisz LG: Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med 1990, 112:352–364.

    PubMed  CAS  Google Scholar 

  25. Manolagas SC, Weinstein RS: New developments in the pathogenesis and treatment of steroid-induced osteoporosis. J Bone Miner Res 1999, 14:1061–1066. An excellent review of presumptive mechanisms. Strongly supports a key role for the osteoblast in GIOP pathogenesis.

    Article  PubMed  CAS  Google Scholar 

  26. Emkey RD, Lindsay R, Lyssy J, et al.: The systemic effect of intraarticular administration of corticosteroid on markers on bone formation and bone resorption in patients with rheumatoid arthritis. Arthritis Rheum 1996, 39:277–282.

    Article  PubMed  CAS  Google Scholar 

  27. Hofbauer LC, Gori F, Riggs L, et al.: Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 1999, 140:4382–4389. Highlights the importance of osteoclast factors in GIOP pathogenesis.

    Article  PubMed  CAS  Google Scholar 

  28. Sasaki N, Kusano E, Ando Y, et al.: Glucocorticoid decreases circulating osteoprotegerin (OPG): possible mechanism for glucocorticoid induced osteoporosis. Nephrol Dial Transplant 2001, 16:479–482.

    Article  PubMed  CAS  Google Scholar 

  29. Dykman TR, Gluck OS, Murphy WA, et al.: Evaluation of factors associated with glucocorticoid-induced osteopenia in patients with rheumatic diseases. Arthritis Rheum 1985, 28:361–368.

    Article  PubMed  CAS  Google Scholar 

  30. Laan RFJM, van Riel PLCM, van de Putte LBA, et al.: Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. Ann Intern Med 1993, 119:963–968.

    PubMed  CAS  Google Scholar 

  31. Verstraeten A, Dequeker J: Vertebral and peripheral bone mineral content and fracture incidence in postmenopausal patients with rheumatoid arthritis: effect of low dose corticosteroids. Ann Rheum Dis 1986, 45:852–857.

    PubMed  CAS  Google Scholar 

  32. Reid IR, Grey AB: Corticosteroid osteoporosis. Bailliere’s Clin Rheumatol 1993, 7:573–587.

    Article  CAS  Google Scholar 

  33. LoCasio V, Bonucci E, Imbimbo B, et al.: Bone loss after glucocorticoid therapy. Bone Mineral 1984, 8:39–51.

    Article  Google Scholar 

  34. Haugeberg G, Uhlig T, Falch JA, et al.: Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis. Arthritis Rheum 2000, 43:522–530. Population-based study documenting the scope of bone disease and potential risk factors among a sizable group of patients with RA.

    Article  PubMed  CAS  Google Scholar 

  35. Peel NFA, Moore DJ, Barrington NA, et al.: Risk of vertebral fracture and relationship to bone mineral density in steroid treated rheumatoid arthritis. Ann Rheum Dis 1995, 54:801–806.

    PubMed  CAS  Google Scholar 

  36. Sambrook PN, Eisman JA, Yeates MG, et al.: Osteoporosis in rheumatoid arthritis: safety of low dose corticosteroids. Ann Rheum Dis 1986, 45:950–953.

    PubMed  CAS  Google Scholar 

  37. O’Malley M, Kenrick AJ, Sartoris DJ, et al.: Axial bone density in rheumatoid arthritis: comparison of dual-energy projection radiography and dual-photon absorptiometry. Radiology 1989, 170:501–505.

    PubMed  CAS  Google Scholar 

  38. Verhoeven AC, Boers M: Limited bone loss due to corticosteroids: a systematic review of prospective studies in rheumatoid arthritis and other diseases. J Rheumatol 1997, 24:1495–1503.

    PubMed  CAS  Google Scholar 

  39. Messina OD, Barreira JC, Zanchetta JR, et al.: Effect of low doses of deflazacort vs prednisone on bone mineral content in premenopausal rheumatoid arthritis. J Rheumatol 1992, 19:1520–1526.

    PubMed  CAS  Google Scholar 

  40. Guyatt GH, Webber CE, Mewa AA, et al.: Determining causation —a case study: adrenocorticosteroids and osteoporosis. J Chronic Dis 1984, 37:343–352.

    Article  PubMed  CAS  Google Scholar 

  41. Sambrook PN, Cohen ML, Eisman JA, et al.: Effects of low dose corticosteroids on bone mass in rheumatoid arthritis: a longitudinal study. Ann Rheum Dis 1989, 48:535–538.

    Article  PubMed  CAS  Google Scholar 

  42. Gough KS, Lilley J, Eyre S, et al.: Generalised bone loss in patients with early rheumatoid arthritis. Lancet 1994, 344:23–27.

    Article  PubMed  CAS  Google Scholar 

  43. Hall GM, Spector TD, Griffin JA, et al.: The effect of rheumatoid arthritis and steroid therapy on bone density in postmenopausal women. Arthritis Rheum 1993, 36:1510–1516.

    Article  PubMed  CAS  Google Scholar 

  44. Lane NE, Pressman AR, Star VL, et al.: Rheumatoid arthritis and bone mineral density in elderly women. J Bone Miner Res 1995, 10:257–263.

    Article  PubMed  CAS  Google Scholar 

  45. Gough A, Sambrook P, Devlin J, et al.: Osteoclastic activation is the principal mechanism leading to secondary osteoporosis in rheumatoid arthritis. J Rheumatol 1998, 25:1282–1289.

    PubMed  CAS  Google Scholar 

  46. Towheed TE, Brouillard D, Yendt E, Anastassiades T:Osteoporosis in rheumatoid arthritis: findings in the metacarpal, spine, and hip and a study of the determinants of both localized and generalized osteopenia. J Rheumatol 1995, 22:440–443.

    PubMed  CAS  Google Scholar 

  47. Spector TD, Hall GM, McCloskey EV, Kanis JA: Risk of vertebral fracture in women with rheumatoid arthritis. Br Med J 1993, 306:558.

    Article  CAS  Google Scholar 

  48. Cooper C, Coupland C, Mitchell M: Rheumatoid arthritis, corticosteroid therapy and hip fracture. Ann Rheum Dis 1995, 54:49–52.

    PubMed  CAS  Google Scholar 

  49. Luengo M, Picado C, Del Rio L, et al.: Vertebral fractures in steroid dependent asthma and involutional osteoporosis: a comparative study. Thorax 1991, 46:803–806.

    PubMed  CAS  Google Scholar 

  50. Selby PL, Halsey JP, Adams KRH, et al.: Corticosteroids do not alter the threshold for vertebral fracture. J Bone Miner Res 2000, 15:952–956.

    Article  PubMed  CAS  Google Scholar 

  51. Naganatham V, Jones G, Nash P, et al.: Vertebral fracture risk with long-term corticosteroid therapy. Arch Int Med 2000, 160:2917–2922.

    Article  Google Scholar 

  52. Evans SF, Davie MWJ: Vertebral fractures and bone mineral density in idiopathic, secondary and corticosteroid associated osteoporosis in men. Ann Rheum Dis 2000, 59:269–275.

    Article  PubMed  CAS  Google Scholar 

  53. Michel BA, Bloch DA, Fries JF: Predictors of fractures in early rheumatoid arthritis. J Rheumatol 1991, 18:804–808.

    PubMed  CAS  Google Scholar 

  54. Baltzan MA, Suissa S, Bauer DC, Cummings SR: Hip fractures attributable to corticosteroid use. Lancet 1999, 353:1327.

    Article  PubMed  CAS  Google Scholar 

  55. McDougall R, Sibley J, Haga M, Russell A: Outcome in patients with rheumatoid arthritis receiving prednisone compared to matched controls. J Rheumatol 1994, 21:1207–1213.

    PubMed  CAS  Google Scholar 

  56. Verhoeven AC, Boers M, te Koppele JM, et al.: Bone turnover, joint damage and bone mineral density in early rheumatoid arthritis treated with combination therapy including highdose prednisolone. Rheumatology (Oxford) 2001, 40:1231–1237. COBRA study data emphasizing the importance of disease activity and glucocorticoid use on bone loss.

    Article  CAS  Google Scholar 

  57. Saag KG, Emkey R, Schnitzer T, et al.: Alendronate for the treatment and prevention of glucocorticoid-induced osteoporosis. N Engl J Med 1998, 339:292–299.

    Article  PubMed  CAS  Google Scholar 

  58. Reid D, Cohen C, Pack S, et al.: Risedronate reduces the incidence of vertebral fractures in patients on chronic corticosteroid therapy. Arthritis Rheum 1998, 41:S136.

    Google Scholar 

  59. Cohen S, Levy RM, Keller M, et al.: Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 1999, 42:2309–2318.

    Article  PubMed  CAS  Google Scholar 

  60. Gluck OS, Murphy WA, Hahn TJ, et al.: Bone loss in adults receiving alternate day glucocorticoid therapy. Arthritis Rheum 1981, 24:892–898.

    Article  PubMed  CAS  Google Scholar 

  61. Kroger H, Honaken R, Saarikoski S, Alhava E: Decreased axial bone mineral density in perimenopausal women with rheumatoid arthritis—a population based study. Ann Rheum Dis 1994, 53:18–23.

    PubMed  CAS  Google Scholar 

  62. Reid IR, Heap SW: Determinants of vertebral mineral density in patients receiving long-term glucocorticoid therapy. Arch Intern Med 1990, 150:2545–2548.

    Article  PubMed  CAS  Google Scholar 

  63. van Staa TP, Leukens HGM, Abenhaim L, et al.: Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford) 2000, 39:1383–1389. Raises concern that fractures may occur earlier than previously suspected in glucocorticoid users.

    Article  Google Scholar 

  64. van Staa TP, Leukens HGM, Abenhaim L, et al.: Use of oral corticosteroids and risk of fracture. J Bone Miner Res 2000, 15:993–1000. Landmark study using the General Practice Research Database of the United Kingdom. Demonstrates increased risk of fractures with even very low-dose glucocorticoids.

    Article  PubMed  Google Scholar 

  65. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis: Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 2001, 44:1496–1503. Updated recommendations based on evidence and consensus.

    Article  Google Scholar 

  66. Solomon DH, Kuntz KK: Should postmenopausal women with rheumatoid arthritis who are starting corticosteroid treatment be screened for osteoporosis? Arthritis Rheum 2000, 43:1967–1975. Provocative investigation arguing for a more conservative approach among lower risk patients.

    Article  PubMed  CAS  Google Scholar 

  67. Kvein TK, Haugeberg G, Uhlig T, et al.: Data driven attempt to create a clinical algorithm for identification of women with rheumatoid arthritis at high risk for osteoporosis. Ann Rheum Dis 2000, 59:805–811.

    Article  Google Scholar 

  68. Harris ED, Emkey RD, Nichols JE, Newberg A: Low dose prednisone therapy in rheumatoid arthritis: a double blind study. J Rheumatol 1983, 10:713–721.

    PubMed  Google Scholar 

  69. Empire Rheumatism Council Sub-Committee: Multi-center controlled trial comparing cortisone acetate and acetyl salicylic acid in the long-term treatment of rheumatoid arthritis. Ann Rheum Dis 1955, 14:353–363.

    Google Scholar 

  70. Joint Committee of the Medical Research Council and Nuffield Foundation on Clinical Trials of Cortisone A, and Other Therapeutic Measures in Chronic Rheumatic Diseases: A comparison of prednisolone with aspirin or other analgesics in the treatment of rheumatoid arthritis. Ann Rheum Dis 1959, 18:173–187.

    Google Scholar 

  71. Bernsten CA, Freyberg RH: Rheumatoid patients after five or more years of corticosteroid treatment: a comparative analysis of 183 cases. Ann Intern Med 1961, 54:938–953.

    Google Scholar 

  72. Million R, Poole P, Kellgren JH, Jayson MI: Long-term study management of rheumatoid arthritis. Lancet 1984, 1:812–816.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Clinical Immunology and Rheumatology, Center for Education and Research on Therapeutics (CERTs) of Musculoskeletal Disorders, University of Alabama at Birmingham, MEB 625, 1813 Sixth Avenue South, 35294-3296, Birmingham, AL, USA

    Kenneth G. Saag MD, MSc

Authors
  1. Kenneth G. Saag MD, MSc
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Saag, K.G. Glucocorticoid use in rheumatoid arthritis. Curr Rheumatol Rep 4, 218–225 (2002). https://doi.org/10.1007/s11926-002-0068-z

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-002-0068-z

Keywords

Search

Navigation